Unknown

Dataset Information

0

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.


ABSTRACT: This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28?weeks' treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels. Body weight, SBP and triglyceride levels were reduced across most respective subgroups, with no significant subgroup-by-treatment interactions. For each treatment, weight loss was numerically greater as baseline body mass index increased. SBP reductions were greater among patients with SBP ?140 vs <140?mm Hg for exenatide once weekly plus dapagliflozin and exenatide once weekly. Reductions in triglyceride levels were greater among patients with baseline triglycerides <1.69 vs ?1.69?mmol/L for each treatment. The combination of exenatide once weekly plus dapagliflozin reduced cardiovascular risk factors across baseline subgroups for each variable to a greater extent than did either individual drug; the greatest effects were observed in the high baseline subgroups for body weight and SBP.

SUBMITTER: Jabbour SA 

PROVIDER: S-EPMC5969082 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

Jabbour Serge A SA   Frías Juan P JP   Guja Cristian C   Hardy Elise E   Ahmed Azazuddin A   Öhman Peter P  

Diabetes, obesity & metabolism 20180204 6


This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks' treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from the DURATION-8 trial of patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. Subgroups of patients were stratified according to their baseline body weight, SBP a  ...[more]

Similar Datasets

| S-EPMC5969323 | biostudies-literature
| S-EPMC6150435 | biostudies-literature
| S-EPMC3263915 | biostudies-literature
| S-EPMC2875434 | biostudies-literature
| S-EPMC5575470 | biostudies-literature
| S-EPMC9346995 | biostudies-literature
| S-EPMC5485171 | biostudies-literature
| S-EPMC7549924 | biostudies-literature
| S-EPMC4621218 | biostudies-literature
| S-EPMC5215525 | biostudies-literature